Prostate Cancer Foundation Reveals Six New Challenge Awards

Prostate Cancer Foundation Reveals Six New Challenge Awards
The Prostate Cancer Foundation (PCF) has announced its six Challenge Awards winners. These awards are focus on improving the treatment of lethal prostate cancer by financially supporting multi-disciplinary teams of researchers. In the beginning of this year, PCF opened applications in the area of treatment sciences, which evaluates patient’s reactions to different therapeutic approaches. An important aspect of projects that receive the Challenge Awards is their research needs to be directly applied in human cases, which can result in a significant impact on therapeutic strategies for prostate cancer patients. “What is so meaningful about these projects is their emphasis on putting the most severe cases of prostate cancer into lasting remissions,” Jonathan W. Simons, MD, president and CEO of the Prostate Cancer Foundation, said in a news release. "The Foundation's support of treatment sciences research has immediate clinical relevancy that will result in game-changing therapies for all men with this disease." After rigorous peer-review of as many as 55 candidates, the winners were selected based on the relevance of their clinical research and the potential of near-term impact on medical standard of care. Furthermore, unfunded high-risk and innovative projects were given priority. One of the winning projects is led by Robert Jeraj, PhD, of the University of Wisconsin Carbone Cancer Center, whose research focuses on molecular imaging to assess metastatic prostate cancer patient’s response to therapy. This type of technology can allow clinicians to predict the time to disease progression for patients receiving enzalutamide, this way improving therapeutic strategy and allowing the development of novel therapies. Another winning project intends to
Subscribe or to access all post and page content.